Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Journal article

EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

Journal article

Mayne K. et al, (2024), Nephrology Dialysis Transplantation

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

Journal article

Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal

Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.

Journal article

Petrucci G. et al, (2024), Eur Heart J, 45, 1355 - 1367

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Journal article

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Empagliflozin in Patients with Chronic Kidney Disease. Reply.

Journal article

Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Journal article

Humbert M. et al, (2023), European Respiratory Journal, 61

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study

Journal article

HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology

Empagliflozin in Patients with Chronic Kidney Disease

Journal article

HERRINGTON W. et al, (2022), New England Journal of Medicine

Load More